ReWalk RoboticsLFWD
LFWD
About: Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
Employees: 108
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
12% more capital invested
Capital invested by funds: $1.82M [Q2] → $2.03M (+$210K) [Q3]
11% more funds holding
Funds holding: 19 [Q2] → 21 (+2) [Q3]
1.82% more ownership
Funds ownership: 5.28% [Q2] → 7.1% (+1.82%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$13
693%
upside
Avg. target
$13
693%
upside
High target
$13
693%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 34% 1-year accuracy 63 / 188 met price target | 693%upside $13 | Buy Reiterated | 13 Nov 2024 |
Financial journalist opinion
Based on 5 articles about LFWD published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities
With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals With recent financing and current capital, the Company believes it has sufficient cash to pursue its goals
Neutral
GlobeNewsWire
1 week ago
Lifeward Cancels Its Extraordinary General Meeting of Shareholders
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), today announced that it has cancelled its previously announced Extraordinary General Meeting of Shareholders that had been scheduled for January 13, 2025. The Board of Directors of Lifeward (the “Board”) has withdrawn from consideration by the shareholders of the Company the proposals set forth in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 25, 2024. The Company's Board intends to present these proposals at a subsequent meeting in 2025.
Neutral
GlobeNewsWire
1 week ago
Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 1,818,183 of the Company's ordinary shares at a purchase price of $2.75 per share. In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to 1,818,183 of the Company's ordinary shares. The warrants have a term of three years, are exercisable immediately following the issuance date and have an exercise price of $2.75 per share.
Neutral
GlobeNewsWire
1 week ago
Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,818,183 of the Company's ordinary shares at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market. In addition, in a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 1,818,183 of the Company's ordinary shares. The warrants will have a term of three years, will be exercisable immediately following the issuance date and have an exercise price of $2.75 per share. The closing of the offering is expected to occur on or about January 8, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
3 weeks ago
Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company's Extraordinary General Meeting of Shareholders (the “Meeting), which was originally scheduled to be held on Monday, December 30, 2024, has been postponed. The Meeting is now scheduled to be held at 10:00 a.m. (Eastern Standard Time) on Monday, January 13, 2025 at the Company's offices at 200 Donald Lynch Blvd., Marlborough, MA 01752, U.S.A. The record date for the Meeting, November 20, 2024, is unchanged and applies to the postponed Meeting.
Neutral
GlobeNewsWire
2 months ago
Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons
Research at the prestigious Semmelweis University, Budapest, Hungary has led the way in achieving government coverage in Hungary with a code for exoskeleton training that expands access to additional spinal cord injury centers
Neutral
Seeking Alpha
2 months ago
Lifeward Ltd. (LFWD) Q3 2024 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Mike Lawless – Chief Financial Officer Larry Jasinski – Chief Executive Officer Conference Call Participants Swayampakula Ramakanth – H.C.
Negative
Zacks Investment Research
2 months ago
Lifeward (LFWD) Reports Q3 Loss, Lags Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.56 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Lifeward Ltd. Reports Third Quarter 2024 Financial Results
Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Neutral
GlobeNewsWire
2 months ago
Lifeward to Report Third Quarter Financial Results on November 12, 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its third quarter 2024 financial results before the markets open on Tuesday, November 12, 2024.
Charts implemented using Lightweight Charts™